Answers are grounded in this paper and cite their sources.
Acne vulgaris is a common inflammatory chronic disease of the pilosebaceous unit. It often requires long-term treatment, resulting in increased demand for topical medications that are popular with patients in order to achieve long-term compliance. Tazarotene foam 0.1% is a novel formulation of tazarotene. We review efficacy and tolerability studies of the new formulation, and suggest a possible place for the product in the management of acne vulgaris.
No takes yet. Share an insight, caveat, or question.
Rigopoulos et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: